Nigeria Lung Cancer Therapeutics Market Report 2022 to 2030

Nigeria Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Nigeria Lung Cancer Therapeutics Market will reach a value of $54 Mn from $27 Mn in 2022, growing at a CAGR of 9.1% during 2022-30. The Lung Cancer Therapeutics Market in Nigeria is dominated by a few domestic pharmaceutical companies such as Neimeth International Pharmaceuticals, Fidson Healthcare Plc, and Swiss Pharma Nigeria Limited. The Lung Cancer Therapeutics Market in Nigeria is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Nigeria lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10NGPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Nigeria AUTHOR: Dr. Vishwa Modhia

Buy Now

Nigeria Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Nigeria Lung Cancer Therapeutics market will reach a value of $54 Mn from $27 Mn in 2022, growing at a CAGR of 9.1% during 2022-30.

Nigeria is a lower middle-income, developing country located in West Africa with a coast on the Gulf of Guinea and the Atlantic Ocean. Lung cancer is a public health concern that imposes a significant socioeconomic and disease burden on the West African sub-region, particularly Nigeria. Lung cancer ranks 14th on the list of newly diagnosed cancers in Nigeria, with a 1.4 % incidence. Exposure to petroleum, gas fumes products, and cement dust at construction sites is frequent among Nigerian urban inhabitants, and the usage of protective air filter masks is non-existent, creating a fertile field for researchers to investigate work-related linked risks of lung cancer.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Nigeria reached 1,295 or 0.09% of total deaths. The age-adjusted Death Rate is 1.37 per 100,000 population ranks Nigeria 178^th in the world. Nigeria's government spends 3.4% of its GDP on healthcare.

Nigeria Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

There has been an increase in awareness initiatives about lung cancer in Nigeria. Campaigns have been developed by organisations such as the Nigerian Cancer Society and the Lagos State University Teaching Hospital to educate the public on the risk factors, symptoms, and prevention of lung cancer. A well-coordinated and regularly monitored awareness and education campaign championed by the Nigerian Thoracic Society and comparable national groups throughout the West African subregion could be an excellent idea in Nigeria. These aspects could boost Nigeria's Lung Cancer Therapeutics market.

Market Restraints

In Nigeria or any other West African country, there is no well-coordinated lung cancer registry. Although operational, the Nigerian National System of Cancer Registries is nevertheless restricted in capacity due to logistical, legal, and sporadic financial issues. In Nigeria, people are generally unaware of the early warning symptoms and risk factors for lung cancer. In 2013, Nigeria had only nine cancer treatment clinics with radiotherapy facilities, despite a population of 172 Mn people, the majority of which were closed. With only four active cancer radiation facilities in 2020, the situation hasn't altered much. These factors may deter new entrants into the Nigeria Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Neimeth International Pharmaceuticals Plc: Neimeth International Pharmaceuticals Plc is a Nigerian pharmaceutical company that specializes in the production and distribution of pharmaceutical products. The company offers a range of lung cancer treatments including chemotherapy drugs
May & Baker Nigeria Plc: May & Baker Nigeria Plc is a Nigerian pharmaceutical company that specializes in the production and distribution of pharmaceutical products. The company offers a range of lung cancer treatments including chemotherapy drugs
Fidson Healthcare Plc: Fidson Healthcare Plc is a Nigerian healthcare company that operates in the pharmaceutical and healthcare sectors. The company offers a range of lung cancer treatments including chemotherapy drugs
Swiss Pharma Nigeria Limited: Swiss Pharma Nigeria Limited is a Nigerian pharmaceutical company that specializes in the production and distribution of pharmaceutical products. The company offers a range of lung cancer treatments including chemotherapy drugs
GSK Nigeria: GSK Nigeria is the Nigerian arm of the global pharmaceutical company, GlaxoSmithKline

Healthcare Policies and Reimbursement Scenarios

The National Agency for Food and Drug Administration and Control (NAFDAC), the National Drug Law Enforcement Agency (NDLEA), and the Federal Ministry of Health are the regulatory authorities in Nigeria with jurisdiction over medications, biologicals, and medical devices. In Nigeria, there is currently no established structure in place for drug price regulation or reimbursement of pharmaceuticals, biologicals, and medical devices.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.